Chordia Therapeutics Inc.
JPX: 190A.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Hiroshi Miyake
- Employees
- 22
- Headquarters
- Fujisawa, Japan
- IPO year
- 2024
- Market cap
- ¥12B
- Website
- https://www.chordiatherapeutics.com/en/index.html
Loading 190A…
Loading profile data…Frequently asked questions about 190A
What does Chordia Therapeutics Inc. (190A.T) do?
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
Where does 190A.T trade?
Chordia Therapeutics Inc. (190A.T) trades on the Tokyo Stock Exchange.
What sector is 190A.T in?
Chordia Therapeutics Inc. (190A.T) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Chordia Therapeutics Inc.?
Hiroshi Miyake is the chief executive officer of Chordia Therapeutics Inc. (190A.T).
Where is Chordia Therapeutics Inc. headquartered?
Chordia Therapeutics Inc. is headquartered in Japan.
Does 190A.T pay a dividend?
Chordia Therapeutics Inc. (190A.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 190A.T go public?
Chordia Therapeutics Inc. (190A.T) completed its initial public offering in 2024.